Kevin B. Kim - Center for Melanoma Research and Treatment, California Pacific Medical Center and Research Institute

基本信息

浏览量：160

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 64 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Combined Pd-1 and Ctla-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma

Erin Mcgillivray,Karam Ashouri,Eftychia Chatziioannou,Jesus Antonio Ocejo Gallegos,Jabra Zarka,Jacob Kechter,Angelina S. Hwang,Kevin Zhang,Milton Barros, Justin Yeh, Ian Okazaki,Andrew B. Crocker, Takuya Maeda,Soo J. Park,Jacob Choi, Mia Andreoli, Tarneem Darwish, David J. Savage,Kevin B. Kim, Jayant Gupta, James Shen,Keisuke Shirai,April Choi,Lori Pai,Vinicius de Lima Vazquez,Justin Moser,Teresa Amaral, Leonel F. Hernandez Aya,Jose Lutzky,Yana G. Najjar,Collin M. Costello,Aaron R. Mangold,Shailender Bhatia,Geoffrey T. Gibney,Jeffrey M. Farma, Gregory A. Daniels,Jeffrey Sosman,Sunandana Chandra,Ankit Mangla,Kathryn Bollin,Patricia Abrao Possik, Carla Daniela Robles-Espinoza,Fumito Ito,Gino K. In

The British journal of dermatologyno. 2 (2025): 316-326

引用0浏览0WOS引用

The Molecular Evolution of Melanoma Distant Metastases

Vladimir Bezrookove,Sara Kianian, Lea McGeever, Robyn Jones,Chongshan Caressi,Mehdi Nosrati,Kevin B. Kim,Stanley P. Leong,James R. Miller III,Pierre-Yves Desprez,Mohammed Kashani-Sabet

JOURNAL OF INVESTIGATIVE DERMATOLOGY（2024）

引用1浏览0WOS引用

Personalized Therapy in Oncology: Melanoma As a Paradigm for Molecular-Targeted Treatment Approaches

Kevin B. Kim

International Archives of Public Health and Community Medicineno. 1 (2024)

引用0浏览0WOS引用

A Phase 1 Study of Triple-Targeted Therapy with BRAF, MEK, and AKT Inhibitors for Patients with BRAF-mutated Cancers

Alain P. Algazi,James Moon,Christopher D. Lao,Bartosz Chmielowski,Kari L. Kendra,Karl D. Lewis,Rene Gonzalez,Kevin Kim,John E. Godwin,Brendan D. Curti,Michaella Latkovic-Taber,Shirley H. Lomeli, Brandon T. Gufford,Philip O. Scumpia,Roger S. Lo,Megan Othus,Antoni Ribas

Cancer（2024）

引用3浏览0WOS引用

Higher Nodal Expression is Often Associated with Poorer Survival in Patients Diagnosed with Melanoma and Treated with Anti-Pd1 Therapy

Philippe D. Gascard, Xianhong Wang,Mehdi Nosrati,Kevin B. Kim,Mohammed Kashani-Sabet,Thea D. Tlsty,Stanley P. Leong,Mary J. C. Hendrix

PATHOLOGY & ONCOLOGY RESEARCH（2024）

引用0浏览0WOS引用

Supplementary Tables S1 and S2 from Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma

David S. Hong,Razelle Kurzrock,Jennifer J. Wheler,Aung Naing, Gerald S. Falchook, Siqing Fu,Kevin B. Kim,Michael A. Davies,Ly M. Nguyen,Goldy C. George,Lucy Xu,Robert Shumaker,Min Ren,Jennifer Mink,Cynthia Bedell,Corina Andresen,Pallavi Sachdev,James P. O'Brien,John Nemunaitis

openalex（2023）

引用0浏览0引用

Data from Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with ≪i>nras</i>-Mutant Melanoma

Martin Schüler,Lisa Zimmer,Kevin B. Kim,Jeffrey A. Sosman,Paolo A. Ascierto,Michael A. Postow,Filip Y.F. De Vos, Carla M.L. van Herpen,Matteo S. Carlino,Douglas B. Johnson,Carola Berking,Micaela B. Reddy,Allison S. Harney,Jordan Berlin,Rodabe N. Amaria

openalex（2023）

引用0浏览0引用

Nanometer-scale Distribution of PD-1 in the Melanoma Tumor Microenvironment

Colin J Comerci,Dannielle G McCarthy,Mehdi Nosrati,Kevin B Kim,Mohammed Kashani-Sabet,W E Moerner,Stanley P Leong

Journal of radiology and oncologyno. 1 (2023): 20-25

引用0浏览0WOS引用

Phase II Study of Niraparib in Patients with Advanced Melanoma with Genetic Homologous Recombination (HR) Mutation/alteration

Kevin B. Kim

JOURNAL OF CLINICAL ONCOLOGY（2023）

引用0浏览0引用

Extended Long-Term Follow-Up of Metastatic Melanoma Patients Treated with Immunotherapy: Late Relapses and Second Primary Melanomas

David R. Minor,Kevin B. Kim, R. Krishna M. Karuturi,Mohammed Kashani-Sabet

Frontiers in Oncology (2023)

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn